New oral drug shows promise for Behçet’s ulcers
A new oral drug is showing promise for treating oral and genital ulcers in people with Behçet’s syndrome, according to research presented this week at the American College of Rheumatology (ACR) meeting in San Diego. The drug apremilast, developed by the biopharmaceutical company Celgene, contains small molecules that modulate several inflammatory pathways and is pending approval by the U.S. Food and Drug Administration, according to an ACR press release. Behçet’s

